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Rituximab 144 is a chimeric anti-CD20 B-cell specific monoclonal antibody approved for the treatment of
low-grade non-Hodgkin’s lymphoma that has shown significant antitumor response and improved
progression free survival either given alone or given as radioimmunoconjugate. CRP has been designed to
focus on the preparation of 177Lu-labeled Rituximab as a therapeutic radiopharmaceutical for the
treatment of lymphomas.
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Aim
Development and preclinical 
evaluation of a sterile kit 
formulation for Rituximab that 
would be suitable for in-house 
preparation of the radiolabeled
MAb for RIT studies in patients.
Expected inputs
1. To find the ways of extending the success of 
radiolabelled anti-CD20 antibodies in 
indolent non-Hodgkin's lymphoma to other 
forms of cancer
2. To improve significantly the efficacy and 
acceptability using radionuclides as-
Lutetium-177 with the lower energy of their 
emission, their relatively long half-life and 
good gamma emission.
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CONCLUSION
The RIT involving the new radioisotopes, now as
a mature technology, can and should enter in a
phase of well designed and focused clinical
developments that may be expected to afford
significant therapeutic advances.
This proposed new radiopharmaceutical - Lu-177
labelled Rituximab can be one of the promising
for the treatment of low-grade non-Hodgkin’s
lymphoma.
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Materials
Monoclonal antibody (mAb)
Trade name: Rituxan, MabThera
(100 mg/10 ml; Roche)
Source: Chimeric monoclonal antibody
Target: CD20, primarily found on the surface of B cells
Chemical data: C6416H9874N1688O1987S44, 144 kD
Chelators
1. p-SCN-Bn-DOTA, (Macrocyclics, B-205)
2. DOTA-NHS-ester, (Macrocyclics, B-280)
3. DOTA (SIGMA)
4. DTPA (SIGMA)
Lutetium-177
Methods
1. mAb purification - preconditioning/purification by
ultrafiltration
2. Conjugation - using a bifunctional chelating agent and
subsequent purification of the conjugate
3. Purification of conjugated mAb
177Lu labeling of the DOTA conjugates
Quality control:
HPLC
TLC
Stability studies
Immunoreactivity
In vitro competitive binding assay, 
Immunoreactive fraction assay, 
Protein characterization by MALDI-ToF
Animal studies - biodistribution studies in normal mice 
and nude mice xenografts followed by imaging studies
Conjugation of Rituximab
with CHX-A”-DTPA and p-SCN-Bn-DOTA, QC, in 
vitro stability and preliminary biodistribution
studies of the labelled conjugate.
Development of a freeze-dried 
kit based on DOTA-Rituximab for labelling
with 177Lu, standardization and further 
development.
Pre-clinical in vitro screening of kit 
formulations of  177Lu-labelled Rituximab, 
QC and binding assays, as well as small 
animal studies
Development of conjugation/labelling
procedure, optimization of the QC of the 
immunoconjugate and determining the 
stability of the labelled product
Production of high specific 
activity, clinical grade 177 Lu, preparation 
and QC of 177Lu-Reditux® and 
177Lu-labelled MabThera®, as well as 
177Lu-DOTA-TATE.
Conjugation of Rituximab with 
DTPA-CHX using different experimental 
conditions, RCP and in vivo assessment 
of tumor uptake.
Development of radiolabelled
Rituximab using  two conjugation 
approaches: with p-SCN-Bn-DTPA and 
p-SCN-Bn-DOTA and optimization of the 
labelling technique
Developing 177Lu-labelled 
bioactive compounds, peptides and 
antibodies and evaluation as therapeutic 
agents.
Evaluation and preclinical studies 
of 177Lu-labelled Rituximab in normal 
and tumor mice.
Conjugation of SCN-Bn-DTPA 
with Rituximab and radiolabelling
with 177Lu and 177Lu-DTPA-Bn-Rituximab, 
QC and biodistribution studies in mice.
Development of suitable animal 
models and in vivo preclinical assessment; 
safety-, kinetic-, excretion-, dosimetry-, 
efficacy results of the produced 
conjugates 
Establishing an 
efficient freeze-drying procedure for 
developing a final kit formulation for 
simple antibody labelling and determining 
the toxicity and therapeutic efficacy of 
the produced kits.
The clinical preparation 
of Lu-177 somatostatin analogues  
and the development of novel 
radiopharmaceuticals based on other peptide 
analogues.
QC and Cytotoxicity to 
inhibit cell proliferation in cell lines for 
radioimmunoconjugates of 177Lu/90Y-
DOTA-h-R3/Trastuzumab
Freeze Drying Procedures
Volume of solution: 1ml
Filled into 2ml glass vial (fill depth = 0.75 cm)
Freeze Drier LABCONCO
Initial procedure
•Ramp from room temperature to -450C 
(ramp rate 10C/min)
•Hold for 2h, ramp to -200C (10C/min)
•Hold for 1h and return to -450C 
•Maintain shelf temperature for 2 hours
•Primary drying was conducted at chamber 
pressure (Pc) of 57 mTorr and shelf temperature 
of -250C and +250C
•Chamber pressure (Pc) was constant for 
primary and secondary drying
•Primary drying for BSA was 4 min and 3 min for 
IgG and mAb
Secondary drying
Shelf temperature of 400C  for 10 hours 
(increase 15-20 hours) 
- (ramp rate 10C/min)
Stability studies:
-IgG – 6 month used
freeze dried formulation
-BSA – 10 month
-mAb – first check for 3 months
ICP-MS analysis 
for the 
determination 
and 
characterization
of the complex 
using “not-
radioactive” Lu
Results
